|1.||Magacho, Leopoldo: 5 articles (07/2008 - 03/2004)|
|2.||Costa, Marcelus Layguel: 3 articles (09/2006 - 03/2006)|
|3.||Craig, Jamie E: 2 articles (12/2015 - 05/2014)|
|4.||Ullrich, Katja: 2 articles (12/2015 - 05/2014)|
|5.||Landers, John: 2 articles (12/2015 - 05/2014)|
|6.||Mulder, Paul G H: 2 articles (04/2012 - 03/2006)|
|7.||van Meurs, Jan C: 2 articles (04/2012 - 03/2006)|
|8.||Jansen, Jan: 2 articles (04/2012 - 03/2006)|
|9.||Ugahary, Luana Cahya: 2 articles (04/2012 - 03/2006)|
|10.||Avila, Marcos Pereira de: 2 articles (07/2008 - 03/2006)|
07/01/1989 - "Therefore, ibopamine seems to have not only a positive inotropic action, but also a potent vasodilating action, leading to both afterload and preload reduction and so to be useful for the treatment of severe congestive heart failure at rest and during exercise after acute and chronic therapy with the drug."
02/01/1986 - "The data suggest than 10 weeks treatment with ibopamine may prevent any deterioration or even produce a mild improvement in patients with very severe congestive heart failure."
09/01/1996 - "Ibopamine exerts hemodynamic and neurohumoral effects, and is beneficial in mild heart failure; however, its additive value in more advanced disease in unclear. "
01/01/1989 - "Ibopamine has been widely shown to cause a significant hemodynamic improvement in patients with heart failure. "
01/01/1983 - "Oral ibopamine shows promise in the treatment of congestive heart failure, but more extensive studies after chronic treatment are desirable."
01/01/1998 - "Ibopamine caused mydriasis (S). "
01/01/1994 - "Ibopamine alone achieved good mydriasis prior to anaesthesia, but this was not maintained intraoperatively. "
02/01/1993 - "Ibopamine produces a dose-dependent mydriasis endowed with very interesting characteristics: rapid onset, marked pupil dilation and rapid return to normal pupillary diameter. "
07/01/1989 - "On the basis of the results obtained, it is concluded that ibopamine is to be preferred when mydriasis is required with good absolute values and brief duration (examinations of the fundus, examinations with Goldmann's lens, etc.), without cycloplegia."
11/01/2003 - "When mydriasis was blocked, ibopamine increased fluorescein clearance by 13% (P<0.0001), which was interpreted as an increased rate of aqueous humor production. "
05/01/2014 - "This study demonstrates that ibopamine has potential as a test to differentiate glaucoma suspects from patients with glaucoma."
12/01/2015 - "An ibopamine challenge is a novel technique for assessing glaucoma using ibopamine, a topical drug which temporarily increases aqueous production. "
05/01/2014 - "Normal eyes with healthy trabecular meshwork show no significant change in intraocular pressure (IOP) following an ibopamine challenge; however, those with glaucoma demonstrate elevated IOP. "
05/01/2014 - "Ibopamine challenge test can be used to differentiate glaucoma suspects from glaucoma patients."
01/01/2013 - "Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma."
11/01/1991 - "Programmed electrical stimulation was performed in 12 patients with moderate to severe congestive heart failure and ventricular tachycardia (VT) to study possible arrhythmogenic properties of ibopamine, a new orally active dopamine agonist. "
11/01/1991 - "Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines."
12/01/1989 - "A trend of improvement in clinical conditions that did not reach statistical significance was noted in each group throughout the study, as a probably "trial effect." Five patients on ibopamine had severe clinical events leading to drug discontinuation (CHF worsening, ventricular tachycardia, elevation of liver transaminases, headache, gastrointestinal disorders) and five on diuretic therapy experienced serious side effects (skin rash, palpitation, atrial fibrillation, elevation of liver transaminases, manic episode). "
02/01/1986 - "Ibopamine, given by the intraduodenal route at a dose of 24 mg/kg, was effective in improving the hemodynamic parameters depressed by myocardial infarction, in particular myocardial contractility and renal hemodynamics. "
04/01/1994 - "In conclusion, in chronic myocardial infarction and CHF in rats, ibopamine reduces the elevated levels of PNE and cardiac ACE. "
04/01/1990 - "To determine the effects of ibopamine on hemodynamic parameters, 9 patients with cardiac dilation after acute myocardial infarction were studied. "
04/01/1990 - "Hemodynamic response to ibopamine in acute myocardial infarction."
04/01/1994 - "Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure."
|1.||Ophthalmic Solutions (Eye Drops)